Loading...

PSYN

PBM

PSYENCE BIOMEDICAL LTD

(PBM)

2025 6-K

Management Changes

10 Nov '25

Management Change

9 Oct '25

Material Agreement

5 Sep '25

Filing Report

28 Aug '25

Foreign Issuer Report

25 Jun '25

Clinical Trial Update

11 Jun '25

Investor Presentation

20 May '25

Psyence Filing Update

6 May '25

Shareholder Meeting Results

23 Apr '25

New CRO Partnership

11 Apr '25

Corporate Update

1 Apr '25

Shareholder Meeting Notice

31 Mar '25

Funding Activities

23 Jan '25

Warrant Issuance

31 Dec '24

Filing Reported

23 Dec '24

Partnership Agreements

19 Dec '24

Filing Announcement

18 Dec '24

Compliance Actions

4 Dec '24

Debt-for-Equity Swap

4 Dec '24

Filing Announcement

3 Dec '24

Filing Update

22 Nov '24

Filing Announcement

12 Nov '24

Filing Notification

1 Nov '24

Annual Meeting Notice

23 Oct '24

Debt-Equity Swaps

8 Oct '24

Share Acquisition

20 Sep '24

NASDAQ Communication

13 Sep '24

License Agreement

5 Sep '24

Investor Presentation Notice

30 Aug '24

Material Agreement Update

20 Aug '24

Stock Purchase Agreement

31 Jul '24

License Agreement Update

24 Jul '24

Convertible Debt Agreement

23 Jul '24

Nasdaq Compliance Notice

5 Jul '24

Debt Financing Update

20 Jun '24

Financing Update

6 Jun '24

Nasdaq Compliance Notice

15 Mar '24

Study Approval Announcement

12 Mar '24

External Links:

SEC

Psyence Biomedical Ltd. reported on June 11, 2025, that its subsidiary signed a Master Services Agreement on May 21, 2025, with Southern Star Research to support a Phase IIb clinical trial for its psilocybin drug candidate, PEX010, aimed at treating adjustment disorder in cancer patients. The trial anticipates enrolling 87 participants and involves various comprehensive CRO services as part of the agreement.

AI Assistant

PSYENCE BIOMEDICAL LTD

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.